Diana V DO, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 4 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · County of Santa Clara
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
22 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. DO’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C143489 · Current
Licensed to practise in California · since 2016 · expires 2028-02-29 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$164,840
Medicare paid this office $164,840 for 557 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 310 | $54,867 | $84 |
| Injection of drug into eye | 86 | $31,585 | $90 |
| Imaging of retina | 537 | $22,336 | $21 |
| Short return visit (20+ min) | 285 | $15,712 | $48 |
| Complex removal of cataract with insertion of prosthetic lens | 14 | $12,891 | $678 |
See all 10 services
| Return visit (30+ min) | 310 | $54,867 | $84 |
| Injection of drug into eye | 86 | $31,585 | $90 |
| Imaging of retina | 537 | $22,336 | $21 |
| Short return visit (20+ min) | 285 | $15,712 | $48 |
| Complex removal of cataract with insertion of prosthetic lens | 14 | $12,891 | $678 |
| New patient visit (45+ min) | 58 | $6,263 | $108 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 79 | $1,225 | $15 |
| New patient visit (30+ min) | 21 | $981 | $47 |
| Measurement of corneal curvature and depth of eye | 17 | $509 | $28 |
| Exam of visual field with extended testing | 17 | $399 | $22 |
Procedures Medicare counted
| Cataract surgery | 30 | More than 53% of doctors who do this |
Who their Medicare patients are
557 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 17% · Women 55% · Also on Medicaid 24% · Health risk score 1.49. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 44% · Coronary heart disease 26% · Chronic kidney disease 25% · Atrial fibrillation 19% · Heart failure 17% · Cancer 17% · Depression 12% · COPD 11% · Stroke 9% · Dementia 5%.
The office billed $1,104,337, Medicare allowed $222,092 and paid $164,840; for 2,677 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 557 | 2,677 | 75 | 1.49 | $1,104,337 | $164,840 |
| 2023 | 449 | 2,234 | 75 | 1.34 | $898,030 | $149,152 |
| 2022 | 486 | 2,457 | 75 | 1.39 | $839,668 | $146,994 |
| 2021 | 448 | 2,284 | 74 | 1.35 | $1,030,584 | $172,423 |
| 2020 | 373 | 1,764 | 73 | 1.57 | $900,459 | $138,305 |
| 2019 | 363 | 1,951 | 74 | 1.49 | $800,525 | $138,815 |
| 2018 | 232 | 1,223 | 74 | 1.42 | $548,188 | $92,709 |
| 2017 | 170 | 731 | 73 | 1.48 | $363,318 | $57,503 |
| 2016 | 527 | 4,238 | 74 | 1.67 | $1,759,276 | $453,910 |
| 2015 | 610 | 4,789 | 74 | 1.58 | $2,572,391 | $703,640 |
| 2014 | 392 | 2,889 | 72 | 1.48 | $1,261,291 | $401,165 |
| 2013 | 230 | 1,284 | 72 | 1.58 | $560,053 | $183,477 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 107 | $28,926 | $87 |
| Short return visit (20+ min) | 349 | $27,605 | $55 |
| Injection of drug into eye | 80 | $26,202 | $97 |
| Imaging of retina | 428 | $20,812 | $22 |
| Complex removal of cataract with insertion of prosthetic lens | 23 | $20,505 | $707 |
| New patient visit (30+ min) | 30 | $1,862 | $62 |
| New patient visit (45+ min) | 14 | $1,522 | $109 |
| Measurement of corneal curvature and depth of eye | 18 | $515 | $29 |
| Exam of visual field with extended testing | 14 | $353 | $22 |
2022: 13 services
| Return visit (30+ min) | 147 | $32,561 | $83 |
| Injection of drug into eye | 82 | $25,942 | $85 |
| Short return visit (20+ min) | 305 | $21,997 | $49 |
| Imaging of retina | 434 | $20,912 | $21 |
| Complex removal of cataract with insertion of prosthetic lens | 18 | $15,637 | $711 |
| New patient visit (45+ min) | 27 | $2,572 | $95 |
| New patient visit (30+ min) | 43 | $2,280 | $53 |
| Measurement of corneal curvature and depth of eye | 26 | $804 | $29 |
| Established patient complete exam of visual system | 13 | $734 | $41 |
| Established patient problem focused exam of visual system | 19 | $621 | $28 |
| Exam of visual field with extended testing | 22 | $431 | $20 |
| Imaging of retina | 27 | $430 | $13 |
| Ct scan of cornea | 12 | $236 | $18 |
2021: 18 services
| Return visit (30+ min) | 191 | $32,955 | $87 |
| Imaging of retina | 379 | $20,221 | $23 |
| Injection of drug into eye | 83 | $20,151 | $92 |
| Short return visit (20+ min) | 243 | $17,418 | $50 |
| Complex removal of cataract with insertion of prosthetic lens | 14 | $13,770 | $689 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $12,232 | $1,019 |
| Removal of cataract with insertion of prosthetic lens | 18 | $11,184 | $486 |
| New patient visit (45+ min) | 52 | $6,202 | $119 |
| Removal of recurring cataract in lens capsule using a laser | 15 | $4,646 | $290 |
| Injection of drug into eye | 12 | $2,360 | $91 |
| Established patient complete exam of visual system | 28 | $2,224 | $57 |
| New patient visit (30+ min) | 30 | $2,042 | $68 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 24 | $1,031 | $38 |
| Imaging of retina | 30 | $687 | $16 |
| Measurement of corneal curvature and depth of eye | 26 | $683 | $26 |
| Exam of visual field with extended testing | 27 | $669 | $22 |
| Established patient problem focused exam of visual system | 13 | $639 | $43 |
| Ct scan of cornea | 11 | $187 | $17 |
2020: 15 services
| Return visit (30+ min) | 225 | $30,311 | $67 |
| Injection of drug into eye | 43 | $18,097 | $99 |
| Removal of cataract with insertion of prosthetic lens | 26 | $16,037 | $486 |
| Imaging of retina | 267 | $12,717 | $22 |
| New patient visit (45+ min) | 82 | $8,446 | $103 |
| Established patient complete exam of visual system | 49 | $4,621 | $59 |
| Injection of drug into eye | 12 | $2,573 | $107 |
| Long return visit (40+ min) | 23 | $2,204 | $96 |
| Imaging of retina | 42 | $1,096 | $18 |
| Imaging of optic nerve | 52 | $993 | $18 |
| Short return visit (20+ min) | 17 | $863 | $45 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $748 | $37 |
| Measurement of corneal curvature and depth of eye | 27 | $707 | $26 |
| Exam of visual field with extended testing | 24 | $656 | $24 |
| Ct scan of cornea | 12 | $194 | $16 |
2019: 17 services
| Return visit (30+ min) | 206 | $29,974 | $66 |
| Removal of cataract with insertion of prosthetic lens | 24 | $19,788 | $600 |
| Injection of drug into eye | 50 | $17,864 | $95 |
| Imaging of retina | 249 | $12,063 | $22 |
| New patient visit (45+ min) | 92 | $10,017 | $109 |
| Established patient complete exam of visual system | 42 | $4,989 | $73 |
| Long return visit (40+ min) | 33 | $3,311 | $100 |
| Injection of drug into eye | 15 | $2,875 | $87 |
| Imaging of retina | 48 | $2,136 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 50 | $1,606 | $18 |
| Imaging of optic nerve | 63 | $1,348 | $20 |
| Short return visit (20+ min) | 27 | $1,258 | $39 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 23 | $1,041 | $40 |
| Established patient problem focused exam of visual system | 14 | $994 | $43 |
| Measurement of corneal curvature and depth of eye | 26 | $758 | $28 |
| Exam of visual field with extended testing | 25 | $663 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 23 | $634 | $15 |
2018: 13 services
| Return visit (30+ min) | 138 | $17,017 | $68 |
| Injection of drug into eye | 38 | $13,296 | $94 |
| Removal of cataract with insertion of prosthetic lens | 18 | $13,226 | $575 |
| New patient visit (45+ min) | 71 | $7,848 | $111 |
| Imaging of retina | 149 | $7,538 | $24 |
| Short return visit (20+ min) | 39 | $3,161 | $41 |
| Examination of eye by ophthalmoscope with retinal drawing | 64 | $2,097 | $19 |
| Long return visit (40+ min) | 15 | $1,218 | $81 |
| Examination of eye by ophthalmoscope with retinal drawing | 32 | $981 | $16 |
| Measurement of corneal curvature and depth of eye | 20 | $592 | $30 |
| Imaging of retina | 13 | $319 | $25 |
| Exam of visual field with extended testing | 13 | $313 | $22 |
| Photography of the retina | 11 | $244 | $20 |
2017: 8 services
| New patient visit (45+ min) | 66 | $7,544 | $114 |
| Injection of drug into eye | 20 | $5,017 | $102 |
| Return visit (30+ min) | 60 | $4,998 | $69 |
| Imaging of retina | 108 | $3,909 | $24 |
| Short return visit (20+ min) | 47 | $3,661 | $45 |
| Examination of eye by ophthalmoscope with retinal drawing | 90 | $3,275 | $20 |
| Long return visit (40+ min) | 14 | $1,295 | $93 |
| New patient visit (30+ min) | 15 | $1,018 | $68 |
2016: 13 services
| Injection, aflibercept, 1 mg | 44 | $153,742 | None |
| Injection, ranibizumab, 0.1 mg | 39 | $103,229 | None |
| Established patient complete exam of visual system | 451 | $60,129 | $68 |
| Photography of the retina | 370 | $26,225 | $40 |
| Injection of drug into eye | 106 | $23,482 | $75 |
| Examination of eye by ophthalmoscope with retinal drawing | 363 | $15,301 | $17 |
| Imaging of retina | 176 | $8,177 | $26 |
| Removal of cataract with insertion of prosthetic lens | 15 | $8,169 | $454 |
| Established patient problem focused exam of visual system | 145 | $7,835 | $46 |
| New patient complete exam of visual system | 32 | $3,040 | $95 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 25 | $2,943 | $95 |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,250 | $54 |
| Measurement of corneal curvature and depth of eye | 11 | $566 | $38 |
2015: 15 services
| Injection, aflibercept, 1 mg | 58 | $305,947 | None |
| Injection, ranibizumab, 0.1 mg | 42 | $130,775 | None |
| Established patient complete exam of visual system | 429 | $71,159 | $84 |
| Photography of the retina | 305 | $26,292 | $55 |
| Injection of drug into eye | 101 | $23,657 | $76 |
| Established patient problem focused exam of visual system | 260 | $19,841 | $58 |
| Imaging of retina | 226 | $15,099 | $32 |
| Examination of eye by ophthalmoscope with retinal drawing | 328 | $13,700 | $18 |
| Destruction of leaking blood vessels of retina using laser | 12 | $10,715 | $714 |
| Removal of cataract with insertion of prosthetic lens | 14 | $7,114 | $418 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 48 | $6,716 | $127 |
| New patient complete exam of visual system | 49 | $4,520 | $92 |
| 2d ultrasound scan of eye tissue and structures | 23 | $1,909 | $71 |
| Exam of visual field with extended testing | 18 | $870 | $44 |
| Return visit (30+ min) | 15 | $791 | $47 |
2014: 16 services
| Injection, aflibercept, 1 mg | 22 | $120,688 | None |
| Injection, ranibizumab, 0.1 mg | 22 | $103,899 | None |
| Established patient complete exam of visual system | 180 | $27,154 | $83 |
| Established patient problem focused exam of visual system | 214 | $17,337 | $57 |
| Photography of the retina | 178 | $14,017 | $53 |
| Examination of eye by ophthalmoscope with retinal drawing | 286 | $13,095 | $20 |
| Injection of drug into eye | 47 | $12,883 | $75 |
| Removal of cataract with insertion of prosthetic lens | 19 | $10,915 | $475 |
| Imaging of retina | 113 | $8,029 | $32 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 31 | $4,292 | $130 |
| New patient complete exam of visual system | 41 | $4,135 | $101 |
| New patient problem focused exam of visual system | 41 | $2,253 | $55 |
| Measurement of corneal curvature and depth of eye | 22 | $1,330 | $58 |
| Exam of visual field with extended testing | 18 | $1,079 | $45 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,072 | $63 |
| Return visit (30+ min) | 11 | $869 | $72 |
2013: 16 services
| Injection, aflibercept, 1 mg | 14 | $72,259 | None |
| Injection, ranibizumab, 0.1 mg | 13 | $42,365 | None |
| Established patient problem focused exam of visual system | 100 | $7,399 | $62 |
| Established patient complete exam of visual system | 54 | $6,950 | $90 |
| Photography of the retina | 95 | $6,640 | $51 |
| Injection of drug into eye | 30 | $6,013 | $76 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | $5,377 | $125 |
| New patient complete exam of visual system | 50 | $5,233 | $105 |
| Examination of eye by ophthalmoscope with retinal drawing | 134 | $4,225 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 73 | $3,026 | $20 |
| Imaging of retina | 49 | $2,093 | $33 |
| New patient problem focused exam of visual system | 30 | $1,800 | $60 |
| New patient visit (45+ min) | 12 | $1,346 | $112 |
| Short return visit (20+ min) | 14 | $781 | $52 |
| Return visit (30+ min) | 11 | $780 | $71 |
| Exam of visual field with extended testing | 13 | $761 | $48 |
Medicaid work
$29,529 in 2024
Medicaid paid $29,529 for 639 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 149 | $19,769 |
| Return visit (30+ min) | 166 | $5,606 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 310 | $3,708 |
| Short return visit (20+ min) | 14 | $447 |
| 2024 | 639 | 4 | 34 | $29,529 |
| 2023 | 694 | 4 | 40 | $21,317 |
| 2022 | 608 | 5 | 38 | $22,122 |
| 2021 | 488 | 4 | 32 | $12,498 |
| 2020 | 656 | 3 | 29 | $11,130 |
| 2019 | 766 | 5 | 32 | $14,958 |
| 2018 | 228 | 3 | 27 | $3,430 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 65 | $10,077 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 362 | $5,603 |
| Return visit (30+ min) | 115 | $3,142 |
| Short return visit (20+ min) | 152 | $2,495 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 68 | $11,828 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 346 | $5,763 |
| Return visit (30+ min) | 93 | $3,008 |
| Short return visit (20+ min) | 76 | $1,486 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 25 | $38 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 309 | $4,370 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 13 | $3,759 |
| Return visit (30+ min) | 95 | $2,827 |
| Short return visit (20+ min) | 71 | $1,542 |
2020
| Return visit (30+ min) | 207 | $6,529 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 361 | $4,288 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 88 | $314 |
2019
| Return visit (30+ min) | 187 | $6,323 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 362 | $3,966 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 67 | $3,886 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 122 | $627 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 28 | $156 |
2018
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 177 | $2,396 |
| Return visit (30+ min) | 33 | $945 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 18 | $89 |
Drugs they prescribed that Part D paid
$13,043
Pharmacies billed $13,043 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 216) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
137 generic and 79 brand-name prescriptions · $13,043 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 22 | $1,050 | $48 |
| Ketorolac Tromethamine | 40 | $529 | $13 |
| Brimonidine | 21 | $503 | $24 |
| Azelastine | 17 | $352 | $21 |
| Latanoprost | 37 | $293 | $8 |
See all 6 drugs
| Prednisolone Acetate | 22 | $1,050 | $48 |
| Ketorolac Tromethamine | 40 | $529 | $13 |
| Brimonidine | 21 | $503 | $24 |
| Azelastine | 17 | $352 | $21 |
| Latanoprost | 37 | $293 | $8 |
| Dorzolamide-Timolol | 20 | $158 | $8 |
Year by year
| 2024 | 216 | 77 | 0% (0) | 37% | $13,043 |
| 2023 | 286 | 84 | 0% (0) | 40% | $22,293 |
| 2022 | 313 | 99 | 0% (0) | None | $34,378 |
| 2021 | 272 | 87 | 0% (0) | 43% | $21,047 |
| 2020 | 243 | 73 | 0% (0) | 39% | $22,601 |
| 2019 | 223 | 66 | None | 46% | $25,683 |
| 2018 | 157 | 45 | 0% (0) | 41% | $9,669 |
| 2017 | 170 | 52 | None | 53% | $13,557 |
| 2016 | 215 | 61 | 0% (0) | 55% | $17,501 |
| 2015 | 118 | 42 | None | 51% | $9,091 |
| 2014 | 94 | 33 | 0% (0) | 60% | $12,101 |
| 2013 | 51 | 24 | 0% (0) | 67% | $5,637 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prednisolone Acetate | 36 | $2,009 | $56 |
| Ketorolac Tromethamine | 61 | $1,443 | $24 |
| Latanoprost | 52 | $858 | $16 |
| Brimonidine | 24 | $254 | $11 |
| Timolol Maleate | 13 | $228 | $18 |
| Dorzolamide | 12 | $211 | $18 |
| Dorzolamide-Timolol | 12 | $189 | $16 |
2022: 9 drugs
| Restasis | 12 | $9,956 | $830 |
| Lumigan | 11 | $7,580 | $689 |
| Prednisolone Acetate | 38 | $1,735 | $46 |
| Ketorolac Tromethamine | 45 | $1,676 | $37 |
| Latanoprost | 76 | $995 | $13 |
| Dorzolamide-Timolol | 20 | $484 | $24 |
| Brimonidine | 13 | $271 | $21 |
| Timolol Maleate | 22 | $229 | $10 |
| Erythromycin | 14 | $168 | $12 |
2021: 8 drugs
| Prednisolone Acetate | 38 | $1,949 | $51 |
| Ketorolac Tromethamine | 53 | $1,493 | $28 |
| Olopatadine | 18 | $1,297 | $72 |
| Latanoprost | 53 | $1,084 | $20 |
| Betaxolol | 14 | $740 | $53 |
| Brimonidine | 18 | $679 | $38 |
| Dorzolamide-Timolol | 13 | $422 | $32 |
| Timolol Maleate | 11 | $157 | $14 |
2020: 8 drugs
| Travoprost | 13 | $3,402 | $262 |
| Olopatadine | 25 | $1,437 | $57 |
| Prednisolone Acetate | 23 | $906 | $39 |
| Ketorolac Tromethamine | 22 | $545 | $25 |
| Betaxolol | 11 | $529 | $48 |
| Latanoprost | 41 | $454 | $11 |
| Timolol Maleate | 15 | $257 | $17 |
| Brimonidine | 17 | $203 | $12 |
2019: 5 drugs
| Restasis | 19 | $12,201 | $642 |
| Olopatadine | 34 | $1,817 | $53 |
| Prednisolone Acetate | 18 | $1,181 | $66 |
| Latanoprost | 57 | $1,041 | $18 |
| Ketorolac Tromethamine | 23 | $602 | $26 |
2018: 5 drugs
| Prednisolone Acetate | 22 | $1,527 | $69 |
| Brimonidine | 11 | $828 | $75 |
| Latanoprost | 46 | $681 | $15 |
| Ketorolac Tromethamine | 21 | $593 | $28 |
| Olopatadine | 11 | $391 | $36 |
2017: 4 drugs
| Combigan | 30 | $5,311 | $177 |
| Prednisolone Acetate | 19 | $1,289 | $68 |
| Ketorolac Tromethamine | 37 | $1,077 | $29 |
| Latanoprost | 38 | $415 | $11 |
2016: 6 drugs
| Combigan | 32 | $5,549 | $173 |
| Durezol | 16 | $2,480 | $155 |
| Prednisolone Acetate | 19 | $785 | $41 |
| Latanoprost | 56 | $710 | $13 |
| Ketorolac Tromethamine | 16 | $608 | $38 |
| Dorzolamide-Timolol | 13 | $242 | $19 |
2015: 2 drugs
| Prednisolone Acetate | 25 | $1,967 | $79 |
| Latanoprost | 27 | $351 | $13 |
2014: 1 drug
| Prednisolone Acetate | 21 | $2,050 | $98 |
Money from drug and device companies
$40,477 in 2025
| 2025 | 11 | 48 | $35,704 | $40,477 |
| 2024 | 9 | 44 | $24,067 | $52,256 |
| 2023 | 10 | 41 | $26,181 | $29,683 |
| 2022 | 9 | 30 | $49,937 | $50,517 |
| 2021 | 8 | 20 | $54,325 | $54,528 |
| 2020 | 8 | 30 | $42,063 | $43,608 |
| 2019 | 9 | 33 | $45,311 | $46,967 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $13,322 | 6 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $7,450 | 18 payments
|
| Alcon Vision | Unity | $5,650 | 5 payments
|
| Ocular Therapeutix | Dextenza | $4,603 | 4 payments
|
| Harrow Eye | Vevye | $2,937 | 2 payments
|
| Astellas Pharma US | Izervay | $2,739 | 3 payments
|
See all 48 published payments
| Mallinckrodt Hospital Products | Meals · 2025-12-18 | Acthar | $14 |
| Alcon Vision | Meals · 2025-12-17 | Unity | $150 |
| Astellas Pharma US | Consulting · 2025-12-09 | Izervay | $2,600 |
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $75 |
| Alcon Vision | Consulting · 2025-11-06 | None | $500 |
| Alcon Vision | Consulting · 2025-10-23 | None | $2,000 |
| Astellas Pharma Global Development | Meals · 2025-10-19 | Izervay | $137 |
| Bausch & Lomb Americas | Meals · 2025-10-13 | Xipere | $111 |
| Regeneron Healthcare Solutions | Consulting · 2025-10-10 | Eylea Hd | $276 |
| Regeneron Healthcare Solutions | Consulting · 2025-10-10 | Eylea Hd | $2,210 |
| Regeneron Pharmaceuticals | Consulting · 2025-10-10 | Eylea | $794 |
| Regeneron Pharmaceuticals | Consulting · 2025-10-10 | Eylea | $2,381 |
| Alcon Vision | Consulting · 2025-10-09 | None | $1,000 |
| Ocular Therapeutix | Consulting · 2025-10-04 | None | $2,000 |
| Apellis Pharmaceuticals | Consulting · 2025-10-03 | Syfovre | $3,258 |
| Alcon Vision | Consulting · 2025-09-18 | None | $2,000 |
| Regeneron Pharmaceuticals | Meals · 2025-09-10 | Eylea Hd | $150 |
| Bausch & Lomb Americas | Meals · 2025-08-22 | Xipere | $108 |
| Astellas Pharma US | Meals · 2025-07-31 | Izervay | $109 |
| Apellis Pharmaceuticals | Meals · 2025-07-31 | Syfovre | $153 |
| Mallinckrodt Hospital Products | Meals · 2025-07-30 | Acthar | $86 |
| Apellis Pharmaceuticals | Consulting · 2025-06-27 | Syfovre | $2,172 |
| Apellis Pharmaceuticals | Meals · 2025-06-05 | Syfovre | $138 |
| Ocular Therapeutix | Meals · 2025-05-14 | Dextenza | $31 |
| Apellis Pharmaceuticals | Consulting · 2025-05-02 | Syfovre | $3,258 |
| Regeneron Pharmaceuticals | Meals · 2025-03-22 | Eylea Hd | $92 |
| Harrow Eye | Consulting · 2025-03-20 | Vevye | $2,800 |
| Bausch & Lomb Americas | Meals · 2025-03-20 | Miebo | $129 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $435 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $435 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $437 |
| Regeneron Pharmaceuticals | Meals · 2025-03-14 | Eylea Hd | $42 |
| Regeneron Pharmaceuticals | Meals · 2025-03-14 | Eylea Hd | $42 |
| Regeneron Pharmaceuticals | Meals · 2025-03-14 | Eylea Hd | $42 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $303 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $302 |
| Regeneron Pharmaceuticals | Travel · 2025-03-14 | Eylea Hd | $301 |
| Astellas Pharma US | Meals · 2025-02-27 | Izervay | $29 |
| Abbvie | Consulting · 2025-02-06 | None | $581 |
| Ocular Therapeutix | Consulting · 2025-02-02 | None | $2,000 |
| Apellis Pharmaceuticals | Consulting · 2025-01-31 | None | $4,344 |
| Harrow Eye | Meals · 2025-01-23 | Triesence | $137 |
| Regeneron Pharmaceuticals | Meals · 2025-01-21 | Eylea Hd | $91 |
| Abbvie | Meals · 2025-01-20 | Ozurdex | $125 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-17 | Eylea Hd | $510 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-17 | Eylea Hd | $510 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-17 | Eylea Hd | $510 |
| Ocular Therapeutix | Travel · 2025-01-01 | None | $572 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $52,256
| Regeneron Pharmaceuticals | Eylea | $26,962 | 16 payments
|
| Ocular Therapeutix | Dextenza | $12,289 | 8 payments
|
| Abbvie | Ozurdex | $7,873 | 2 payments
|
| EyePoint Pharmaceuticals US | Eyp-1901 | $2,532 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $1,899 | 2 payments
|
| Astellas Pharma US | Izervay | $270 | 8 payments
|
| Bausch & Lomb Americas | Xipere | $269 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $127 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $36 | 1 payment
|
2023: $29,683
| Regeneron Healthcare Solutions | Eylea | $14,056 | 11 payments
|
| Biogen | None | $5,177 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $4,826 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $3,530 | 5 payments
|
| AbbVie | Ozurdex | $1,311 | 9 payments
|
| Bausch & Lomb Americas | Xipere | $359 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $139 | 3 payments
|
| Genentech | Vabysmo | $120 | 1 payment
|
| Ocular Therapeutix | Dextenza | $90 | 1 payment
|
| Astellas Pharma US | None | $75 | 1 payment
|
2022: $50,517
| Regeneron Healthcare Solutions | Eylea | $20,240 | 10 payments
|
| Apellis Pharmaceuticals | None | $9,070 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $8,464 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $5,250 | 1 payment
|
| Bausch & Lomb Americas | Visudyne | $2,832 | 3 payments
|
| Alcon Vision | None | $2,340 | 1 payment
|
| Genentech | Vabysmo | $2,135 | 4 payments
|
| Alimera Sciences | Iluvien | $125 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $61 | 2 payments
|
2021: $54,528
| Novartis Pharma AG | Beovu | $14,863 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $11,880 | 5 payments
|
| Regeneron Pharmaceuticals | Eylea | $11,340 | 4 payments
|
| Novartis Pharmaceuticals | Beovu | $10,763 | 2 payments
|
| Aerie Pharmaceuticals | None | $4,680 | 2 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $800 | 1 payment
|
| Allergan | Durysta | $114 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $88 | 3 payments
|
2020: $43,608
| Regeneron Healthcare Solutions | Eylea | $13,500 | 5 payments
|
| Regeneron Pharmaceuticals | Eylea | $8,970 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $6,824 | 10 payments
|
| Novartis Pharmaceuticals | Beovu | $6,114 | 4 payments
|
| Aerie Pharmaceuticals | None | $4,680 | 2 payments
|
| Allergan | None | $1,901 | 3 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $1,600 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $46,967
| F. Hoffmann-La Roche AG | Non-Covered Product | $14,246 | 10 payments
|
| Aerie Pharmaceuticals | Rocklatan | $13,557 | 7 payments
|
| Genentech | Lucentis | $7,812 | 8 payments
|
| Boehringer Ingelheim International GmbH | None | $6,300 | 1 payment
|
| Allergan | Ozurdex | $2,625 | 2 payments
|
| Novartis Pharmaceuticals | None | $2,356 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $29 | 1 payment
|
| Regeneron Pharmaceuticals | None | $27 | 1 payment
|
| AbbVie | Humira | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2025 | Their institution | $40,845 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2021 | Their institution | $27,866 |
| Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2024 | Their institution | $18,861 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2021 | Their institution | $18,535 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2019 | Their institution | $14,113 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2021 | This clinician | $11,342 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2023 | Their institution | $10,592 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2022 | This clinician | $8,948 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2022 | This clinician | $8,766 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2020 | Their institution | $7,561 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2025 | This clinician | $7,316 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2025 | This clinician | $4,168 |
| Regeneron Pharmaceuticals, Inc. · A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of Vegf Trap-Eye in Patients With Diabetic Macular Edema · 2021 | This clinician | $4,005 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2023 | This clinician | $3,777 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2024 | Their institution | $3,264 |
| Regeneron Pharmaceuticals, Inc. · A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of Vegf Trap-Eye in Patients With Diabetic Macular Edema · 2019 | This clinician | $3,167 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2022 | Their institution | $2,795 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2021 | This clinician | $2,278 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2024 | This clinician | $2,055 |
| F. Hoffmann-La Roche AG · Harbor 1 · 2023 | This clinician | $1,961 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2020 | This clinician | $1,829 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Anti-Vascular Endothelial Growth Factor Treatment Regimens for Neovascular Age-Related Macular Degeneration A Network Meta-Analysis · 2020 | This clinician | $1,510 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2025 | Their institution | $1,340 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Different Anti-Vascular Endothelial Growth Factor Treatment Regimens in Patients With Neovascular Age-Related Macular Degeneration A Network Meta-Analysis · 2020 | This clinician | $910 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2022 | Their institution | $900 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2020 | This clinician | $488 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Different Anti-Vegf Treatment Regimens in Patients With Namd A Network Meta-Analysis · 2020 | This clinician | $425 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Anti-Vascular Endothelial Growth Factor Vegf Treatment Regimens for Neovascular Age-Related Macular Degeneration Namd A Network Meta-Analysis · 2020 | This clinician | $286 |
Professional record
- NPI
- 1245270313
- Licence
- CA C143489, MD D59856California C143489: Current · expires 2028-02-29
- Trained
- University of California, San Francisco School of Medicine, 1999
- Group
- Stanford Health Care · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- MD 401799400
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2006-06-07
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.